Cencora reported $84.8 billion of revenue in the three months ended June 30, up 5.1% from the comparable period. The striking part was what happened after the sales: gross profit rose 24.1% to $3.6 billion, and operating income climbed 29.1% to $1.1 billion.
That looks like a distribution business finding more room in a famously narrow-margin model. Gross margin widened from 3.6% to 4.3%, while operating margin reached 1.3%. Net income, though, rose only 11.1% to $763.5 million, leaving net margin unchanged at 0.9%.
The missing piece is financing. Cencora borrowed to help finance its February acquisition of OneOncology, and interest expense increased sharply in the nine months ended June 30.
Management attributes the gross-profit improvement to both reportable segments and higher LIFO credits, while separately identifying OneOncology as a driver of Healthcare Solutions’ margin improvement. It also identifies a product mix that pulled in the opposite direction:
"Healthcare Solutions’ gross profit margin of 3.17% in the current year quarter increased 63 basis points from the prior year quarter primarily due to the February 2026 acquisition of OneOncology, offset in part by higher sales of GLP-1s, which have lower gross profit margins."
Cencora 10-Q, 2026-08-05
In plain English, the acquisition lifted Healthcare Solutions’ margin, while higher sales of GLP-1 drugs diluted it. The company does not break out how much of the consolidated improvement came from each factor, but it does name both sides of the equation.
The debt side is less subtle. Cencora issued $3.0 billion of senior notes and took on $1.5 billion of variable-rate term loans in February to finance part of OneOncology. For the nine months ended June 30, net interest expense increased $139.9 million, or 65.4%, from the comparable period.
"The increase in interest expense was primarily due to the issuance of our $3.0 billion of senior notes and the $1.5 billion of variable-rate term loans in February 2026, which we borrowed to finance a portion of the OneOncology acquisition, and higher interest expense at our European distribution business, offset in part by lower interest on our domestic revolving credit facility borrowings and lower interest expense on the $0.4 billion balance remaining on the $1.5 billion variable-rate term loan, which we borrowed in January 2025 to finance a portion of the RCA acquisition."
Cencora 10-Q, 2026-08-05
That leaves a simple tension: the operating business produced more profit from each dollar of revenue, but the acquisition financing is contributing to higher interest expense. The latest filing shows cash of $2.8 billion, up 26.1% year over year, so the balance sheet did not move in only one direction. It also shows inventory up 4.4% and receivables up 3.6%, both broadly tracking the sales increase.
Cencora says those working-capital increases supported higher business volume and reflected the timing of scheduled customer payments. Its annual record supplies some context: fiscal 2025 revenue grew 9.3% to $321.3 billion, while operating margin was 0.8%. The company has been growing at scale, but the margin remains measured in pennies per dollar, which makes financing costs unusually visible.
Shares closed at $306.30 on August 4, down 0.7% that day. At that price, Cencora carried a 38.5-times price-to-earnings multiple, according to the supplied valuation data. The number matters here not as a verdict, but because a narrow-margin distributor has less room for a rising interest bill before it reaches per-share earnings.
Cencora has explained where the new interest expense came from. It has not answered how much of OneOncology’s margin contribution remains after that financing cost. How much of the gross-profit gain will still be visible after the acquisition debt is fully reflected in Cencora’s earnings?